Charles L Shapiro MD

Charles L Shapiro MD
ProfessorCollege of Medicineshapiro.73@osu.edu
B405 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-6401Fax: 614-293-7529
  • Cancer Control

Current Publications

  • Glaser RYoga's Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial.J Clin Oncol 32 1040-9 4/1/2014
  • Croce CMProtective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.Proc Natl Acad Sci U S A 111 4536-41 3/25/2014
  • Shapiro CLPhase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer.Clin Breast Cancer 2/20/2014
  • Farrar WQuality improvement in breast cancer project: compliance with antiresorptive agents and changing patterns of drug use.J Natl Compr Canc Netw 12 Suppl 1 S33-5 2/1/2014
  • Couch FJGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Carcinogenesis 1/23/2014
  • Huebner KmicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.Oncotarget 1/21/2014
  • Huebner KAndrogen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.PLoS One 9 e88525 1/1/2014
  • Doo L, Shapiro CLSkeletal manifestations of treatment of breast cancer on premenopausal women.Curr Osteoporos Rep 11 311-8 12/1/2013
  • Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das HHuman V?2Vd2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.Int J Cancer 133 2133-44 11/1/2013
  • Shapiro CLRandomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.Clin Breast Cancer 10/26/2013
  • Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RMPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21(10) 2845-51 10/1/2013
  • Wesolowski RDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Support Care Cancer 21(10) 2679-86 10/1/2013
  • Mrózek E, Povoski SP, Shapiro CLThe challenges of individualized care for older patients with localized breast cancer.Expert Rev Anticancer Ther 13(8) 963-73 8/1/2013
  • Shapiro CLBisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective.J Clin Oncol 31(21) 2648-50 7/20/2013
  • Wang C, Pécot T, Zynger DL, Machiraju R, Shapiro CL, Huang KIdentifying survival associated morphological features of triple negative breast cancer using multiple datasets.J Am Med Inform Assoc 20(4) 680-7 7/1/2013
  • Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, Yin X, Chang Y, Zmuda EJ, O'Toole SA, Millar EK, Roller SL, Shapiro CL, Ostrowski MC, Sutherland RL, Hai TTranscription factor ATF3 links host adaptive response to breast cancer metastasis.J Clin Invest 123(7) 2893-906 7/1/2013
  • Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CLIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.Ann Oncol 24(6) 1526-33 6/1/2013
  • Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CMIn vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.J Exp Med 210(5) 951-68 5/6/2013
  • Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71(5) 1183-90 5/1/2013
  • Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CLEffect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA 309(13) 1359-67 4/3/2013
  • Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
  • Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner KIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.PLoS One 8(2) e55910 1/1/2013
  • Paskett EDImproving Symptom Communication Through Personal Digital Assistants: The CHAT (Communicating Health Assisted by Technology) Project.J Natl Cancer Inst Monogr 2013(47) 153-61 1/1/2013
  • Lustberg MB, Reinbolt RE, Shapiro CLBone health in adult cancer survivorship.J Clin Oncol 30(30) 3665-74 10/20/2012
  • Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder SHedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.Cancer Res 72(19) 5048-59 10/1/2012
  • Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MVMicrocirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.Magn Reson Imaging 30(8) 1059-67 10/1/2012
  • Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer 20(9) 1991-7 9/1/2012
  • Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL, Huebner KStem cell-related markers in primary breast cancers and associated metastatic lesions.Mod Pathol 25(7) 949-55 7/1/2012
  • Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CLPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.Cancer Chemother Pharmacol 70(1) 49-56 7/1/2012
  • Chuang HC, Kapuriya N, Kulp SK, Chen C, Shapiro CLDifferential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.Breast Cancer Res Treat 134(2) 649-59 7/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu